Executive chairman Paul Hopper authorised the announcement, noting that Radiopharm’s strategy is to develop a differentiated platform of radiopharmaceutical products across peptides, small molecules, and antibodies.
Radiopharm Theranostics accelerates HER2 cancer trial after positive safety review
October 1, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 4 September
September 4, 2026 - - Podcast -
A three-pronged expansion of Commonwealth reach in therapeutic-goods regulation
September 4, 2026 - - Latest News -
If the government gives itself more power, don't be surprised when they use it
September 4, 2026 - - Latest News -
Medicines Australia calls for doubling of PBS medicines investment
September 4, 2026 - - Latest News -
Gilead returns to Medicines Australia as industry prepares to make the case for innovation
September 3, 2026 - - Latest News -
Combined monitoring of key indicators as the future of diabetes care
September 3, 2026 - - Latest News -
The live lesson from the UK on who holds the levers and how they use them
September 3, 2026 - - Latest News
